Table 4. Nonhaematological toxicity in both treatment arms.
|
CIP (n=101)
|
CEP (n=98)
|
|||
|---|---|---|---|---|
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
| Toxicity | % | % | % | % |
| Allergy | 13 | 2 | 8 | 0 |
| Cardiac | 1 | 1 | 0 | 0 |
| Vascular | 0 | 1 | 2 | 0 |
| Artromyalgia | 37 | 5 | 39 | 5 |
| Nausea | 78 | 21 | 76 | 24 |
| Vomiting | 73 | 24 | 80 | 17 |
| Mucositis | 43 | 3 | 53 | 2 |
| Fevera | 38 | 2 | 19 | 0 |
| Infection | 16 | 2 | 15 | 2 |
| Neurotoxicity | 59 | 3 | 69 | 0 |
| Alopaecia | 0 | 98 | 0 | 98 |
Abbreviations: CEP=cisplatin/paclitaxel/epirubicin; CIP=cisplatin/paclitaxel/ifosfamide.
a
Statistically significant difference between the two treatment regimens (P<0.01).